Back to Feed
ClinicalTrials.gov|Clinical Trial
CD19/CD22 CAR-T as First-line Consolidation in Follicular Lymphoma
Liping Dou
Abstract
The purpose of this study is to determine the efficacy and safety of CD19/CD22 Chimeric Antigen Receptor (CAR) T-Cell immunotherapy as first-line consolidation therapy in patients with follicular lymphoma. Phase: PHASE2 Status: RECRUITING Conditions: Lymphoma Interventions: CD22/CD19 CAR-T cell immunotherapy
Keywords
Lymphoma